Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI